Prevision raised $5.4m. What does open source offer?
The lab assay and OpenOnco answer different questions. Open code makes rules inspectable; funding alone says nothing about patient outcomes.
Written retrospectively and published on October 17, 2026.
A company announcement is not independent evidence of clinical benefit. This comparison is informational, not medical advice. This article does not replace a doctor.
On 24 September, Prevision Medicine announced a $5.4m seed round for its functional oncology testing platform. According to the company, PrevisionOne measures how living tumor cells respond to drugs. The funding figure is its announcement, not an independently measured treatment benefit.
The overlap with OpenOnco is the treatment discussion, not the method. Prevision describes a proprietary laboratory assay requiring a patient sample; OpenOnco publishes source-linked deterministic rules and MIT-licensed code, with a free browser Plan Builder. A rule cannot measure a tumor's drug response, and a laboratory result does not replace guideline review.
Open source wins on a narrower, verifiable point: anyone can inspect, reuse and challenge OpenOnco's code. That does not establish better accuracy or patient outcomes than Prevision. The cited company pages do not provide a head-to-head comparison; their clinical claims need to be assessed on their own evidence.
Illustrative discussion only: a fictional tumor board receiving a drug-sensitivity report would check the assay's validation beside established evidence. OpenOnco could organize cited pathway options, but neither tool should choose treatment for a real person without qualified clinical review. Comparison checked 17 October 2026.
Comments
Threads are public and indexed — please keep personal medical data out of them. Found a clinical error? Open an issue instead.
Comments are not switched on yet — the backend still needs to be configured.